GeneDx Holdings Corp.

GeneDx Holdings Corp. provides genomic testing services. The company offers ExomeDx™ and GenomeDx™ tests, which are ranked #1 by expert geneticists and have received FDA Breakthrough Device Designation. These tests enable clinicians to provide precise, fast, and actionable diagnoses. GeneDx Holdings combines clinical expertise, advanced technology, and its proprietary GeneDx Infinity™ dataset to power these tests. The GeneDx Infinity™ dataset also supports discovery for biopharma and aims to drive the future of precision genetic medicine. GeneDx was founded in 2000 by scientists from the National Institutes of Health with the goal of making genetic testing accessible for patients with rare diseases. The company became a leader in genomics, establishing methods for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. Over 25 years, GeneDx has built one of the world's largest rare disease datasets, GeneDx Infinity™. GeneDx Holdings acquired GeneDx, LLC on April 29, 2022, and Fabric Genomics, Inc. on May 5, 2025. The company's Class A common stock and public warrants are listed on the Nasdaq Global Select Market under the symbols "WGS" and "WGSWW," respectively.